Bolt Biotherapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Bolt Biotherapeutics, Inc. (BOLT) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-06-30 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 1 month | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 10-K · filed 2026-03-12 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |